title: Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.
authors.affiliation: Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia.|Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Marina
authors.initials: M
authors.lastname: Ali
authors.affiliation: Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia.|Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Rachael
authors.initials: R
authors.lastname: Anforth
authors.affiliation: Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia.|Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Flavia
authors.initials: F
authors.lastname: Senetiner
authors.affiliation: Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia.|Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Giuliana
authors.initials: G
authors.lastname: Carlos
authors.affiliation: Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia.|Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
authors.forename: Pablo
authors.initials: P
authors.lastname: Fernandez-Penas
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D007211:Indoles / Q000009:adverse effects; D007642:Keratosis / Q000139:chemically induced*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D010091:Oximes / Q000009:adverse effects; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000139:chemically induced*; D013449:Sulfonamides / Q000009:adverse effects; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib
keywords: BRAF inhibitors; melanoma; squamous cell carcinoma; verrucal keratosis